Oncology Ultrasound

Catch up on the latest episodes of our Breast Imaging in Focus series with Manisha Bahl, MD, MPH, FSBI, discussing research on a variety of topics including breast arterial calcification on mammograms, automated breast ultrasound, AI and GLP-1 receptor agonists.

In a recently published review of the BI-RADS v2025 manual, leading breast radiologists offered pertinent insights on key changes for reporting of mammogram, breast ultrasound and breast MRI interpretation and assessment.

Catch up on the top AI-related news and research in radiology over the past month.

A model combining MRI and ultrasound findings yielded a 93 percent AUC for predicting microvascular invasion in hepatocellular carcinoma.

While use of an AI software demonstrated significantly higher accuracy in evaluating BI-RADS 2 presentations and no significant difference with radiologists in BI-RADS 4 assessments of breast ultrasound in a sub-analysis, researchers noted the exclusion of galactoceles, fluid collections and skin lesions that are commonly found in pregnant and lactating women.

Catch up on a variety of new FDA clearances in radiology from the past week.

Reportedly trained on thousands of cardiac ultrasound images, the Ejection Fraction (EF) AI tool provides automated measurement of left ventricular ejection fraction (LVEF) in seconds.

Catch up on the most-well viewed radiology content in May 2026.

Cystadenomas and cystadenofibromas accounted for 46 percent of benign lesions initially scored as O-RADS 4 and 5 lesions on pelvic ultrasound, according to newly published research.

In a recent interview, Manisha Bahl, MD, discussed new breast ultrasound research findings that showed 16 percent higher specificity for breast cancer with adjunctive AI in comparison to unassisted interpretation.

Approximately 15 percent of women with abnormal screening mammography results and adverse social determinants of health (SDOH) had follow-up diagnostic mammography or breast ultrasound within 30 days, according to multinational research presented at the Society of Breast Imaging symposium.

Catch up on a variety of new FDA clearances and approvals in radiology from the past week.

Providing 3D ultrasound tomographic views, the Breast Acoustic CT device has an updated configuration that reportedly improves coverage and visualization of posterior breast tissue.

Catch up on the top radiology content of the past week.

In addition to significantly reduced interpretation time, researchers found that adjunctive AI with ultrasound resulted in accuracy improvements of greater than 7 percent for nodule echogenicity and 16 percent for nodule margin assessments.

In comparison to LI-RADS version 2018 for MRI assessment, the use of perfluorobutane-enhanced ultrasound incorporating Kupffer-phase findings yielded comparable sensitivity and specificity for detecting hepatocellular carcinoma (HCC) nodules < 20 mm in high-risk patients, according to new research.

Offering AI-powered automation features and advanced imaging capabilities, the new LOGIQ E10 series, the LOGIC Fortis™ and the LOGIQ Totus™ ultrasound platforms will be introduced at the European Congress of Radiology in March.

Catch up on the top radiology content of the past week.

In a prospective comparison with prior criteria for evaluating hepatocellular carcinoma surveillance, the American Association for the Study of Liver Diseases (AASLD) version 2023 system offered significantly higher sensitivity.

Catch up on a variety of new FDA clearances in radiology from the past week.

Offering a biocompatible, non-metallic alternative to metallic tumor markers, the VM1 tumor marker reportedly offers artifact-free visibility across a variety of breast imaging including mammography, ultrasound and MRI.

Offering compact versatility for an array of clinical settings, the ASUS Handheld Ultrasound LU800 is reportedly the first handheld device to be supported across Android, Chrome, iOS and Windows operating systems.

Catch up on the most well-viewed ultrasound content from 2025.

Preliminary research has shown that the Vanquish Water Vapor Ablation System eliminated MRI-visible intermediate-risk PCa in over 90 percent of patients.

The newly launched Compass AI software platform reportedly facilitates a 94 percent compliance rate for documentation of point-of-care ultrasound (POCUS) exams.